Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stellate Ganglion Blockade for VMS
NCT02907983Phase 2Withdrawn
- Sponsor
- Northwestern University
- Start
- Jul 2018
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bupivacaine in vasomotor symptoms (2 arms), sponsored by Northwestern University. Primary endpoint: Changes from baseline and intensity of subjective hot flashes (HF) at 6 months. Planned start Jul 2018; status: withdrawn.
02
Drugs
bupivacaine
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT02907983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02907983.